The balance sheet of Cheshire’s Alexion Pharmaceuticals Inc. continued to reap in the fourth quarter the benefits of marketing one of the world’s most expensive orphan drugs to treat a rare blood anemia and other disorders.
For three months ended Dec. 31, the maker of Soliris netted $81 million, or 40 cents a share, up from $48.2 million, or 25 cents a share, netted the same period in 2011.
Fourth-quarter sales rose 41 percent to $320.5 million from $227.6 million a year earlier.
For 2012, Alexion netted $254.8 million, or $1.28 a share, up from year-ago net of $175.3 million, or 91 cents a share.
Full-year sales were $1.13 billion vs. $783.4 million.
For 2013, the company projects global sales in the range of $1.49 billion to $1.51 billion, with earnings in the range of $2.82 to $2.92 a share.
